Other experimental therapies that can be delivered with a delay after stroke include antibodies against Nogo‐A, which also induce neuroplasticity of cortical efferents.51, 52, 53 Given the importance of the CST for spontaneous recovery after stroke,54 these novel strategies offer encouraging prospects for enhancing neural repair. The gene discussed is RTN4; the disease is Stroke.